(NASDAQ: AURA) Aura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Aura Biosciences's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast AURA's revenue for 2026 to be $0, with the lowest AURA revenue forecast at $0, and the highest AURA revenue forecast at $0. On average, 5 Wall Street analysts forecast AURA's revenue for 2027 to be $907,906,237, with the lowest AURA revenue forecast at $0, and the highest AURA revenue forecast at $1,490,167,710.
In 2028, AURA is forecast to generate $2,420,998,627 in revenue, with the lowest revenue forecast at $622,332,036 and the highest revenue forecast at $3,875,922,023.